

Supplementary Information

Ruthenium(II)-mercapto Complexes with Anticancer Activity Interact with Topoisomerase IB

Monize M. da Silva,^{*a} Mariana S. de Camargo,^a Silvia Castelli,^b Rone A. de Grandis,^c Eduardo E. Castellano,^d Victor M. Deflon,^e Marcia R. Cominetti,^f Alessandro Desideri^b and Alzir A. Batista  ^{*,a}

^aDepartamento de Química, Universidade Federal de São Carlos, CP 676, 13565-905 São Carlos-SP, Brazil

^bDipartimento di Biologia, Università Tor Vergata di Roma, 00133 Rome, Italy

^cDepartamento de Ciências Biológicas, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista (Unesp), 14801-902 Araraquara-SP, Brazil

^dInstituto de Física de São Carlos, Universidade de São Paulo, CP 369, 13560-970 São Carlos-SP, Brazil

^eInstituto de Química de São Carlos, Universidade de São Paulo, CP 780, 13560-970 São Carlos-SP, Brazil

^fDepartamento de Gerontologia, Universidade Federal de São Carlos, CP 676, 13565-905 São Carlos-SP, Brazil

*e-mail: monize_martins@yahoo.com.br; daab@ufscar.br




Figure S1. Absorption spectra of the complexes **1-4** in the UV-Vis region for the complexes, in CH_2Cl_2 .




Figure S2. Cyclic voltammograms of the complexes **1-4**, in CH_2Cl_2 (0.1 M PTBA, 100 mV s^{-1} , Ag/AgCl), platinum working electrode. Complex **1**: $[\text{Ru}(\text{mtz})_2(\text{dppb})]$; complex **2**: $[\text{Ru}(\text{mmi})_2(\text{dppb})]$; complex **3**: $[\text{Ru}(\text{dmp})_2(\text{dppb})]$; complex **4**: $[\text{Ru}(\text{mpca})_2(\text{dppb})]$, mtz = 2-mercaptopthiazoline; mmi = 2-mercpto-1-methyl-imidazole; dmp = 4,6-diamino-2-mercaptopurimidine; mpca = 6-mercaptopurine-3-carboxylic acid; dppb = 1,4-bis(diphenylphosphino)butane.






Figure S3. Cyclic voltammogram of the free 2-mercaptop-1-methyl-imidazole, in CH_2Cl_2 (0.1 M perchlorate tetrabutyl ammonium (PTBA), 100 mV s^{-1} , Ag/AgCl), platinum working electrode.







Figure S4. IR spectra of the **1-4** complexes, in CsI pellets. Complex **1**: [Ru(mtz)₂(dppb)]; complex **2**: [Ru(mmi)₂(dppb)]; complex **3**: [Ru(dmp)₂(dppb)]; complex **4**: [Ru(mpca)₂(dppb)].




Figure S5. $^{31}\text{P}\{^1\text{H}\}$ (162 MHz, $\text{CH}_2\text{Cl}_2/\text{D}_2\text{O}$) NMR spectra of the complexes **1-4**.





Figure S6. ^1H NMR (400 MHz) spectra of the complexes in CD_2Cl_2 (complexes **1** and **2**) and in $\text{DMSO}-d_6$ (complexes **3** and **4**).






Figure S7. Contour map of correlation spectroscopy (COSY) (^1H - ^1H) for complexes in CD_2Cl_2 (complexes **1** and **2**) and $\text{DMSO}-d_6$ (complexes **3** and **4**).









Figure S8. ^{13}C NMR (100 MHz) spectra for complexes in CD_2Cl_2 (complexes **1** and **2**) and $\text{DMSO}-d_6$ (complexes **3** and **4**).







Figure S9. Contour map of heteronuclear single quantum coherence spectroscopy (HSQC) (^1H - ^{13}C) for complexes in CD_2Cl_2 (complexes **1** and **2**) and $\text{DMSO}-d_6$ (complexes **3** and **4**).

2.1

72 h



48 h



0 h



(a)

2.2


72 h



48 h



0 h



(b)

2.3

72 h

48 h

0 h

(c)

2.4

72 h

48 h

0 h

(d)






Figure S10. Stability of the complexes, for 72 h, in DMSO (0.1%)/DMEM solutions. ^{31}P NMR (162 MHz) (a) complex **1**: $[\text{Ru}(\text{mtz})_2(\text{dppb})]$; (b) complex **2**: $[\text{Ru}(\text{mmi})_2(\text{dppb})]$; (c) complex **3**: $[\text{Ru}(\text{dmp})_2(\text{dppb})]$; (d) complex **4**: $[\text{Ru}(\text{mpca})_2(\text{dppb})]$.

MDA-MB-231



MCF-7






Figure S11. Graphics of half maximal inhibitory concentration (IC_{50}) for the complexes (2-4) with respect different cell lines. The complex **1** was not cytotoxic.

Table S1. Crystal and refinement data for (**1**), (**2**), (**3**) and (**4**)

Compound	1	2	3	4
Empirical formula	C ₃₄ H ₃₆ N ₂ P ₂ RuS ₄	C ₃₆ H ₃₈ N ₄ P ₂ RuS ₂	C ₃₆ H ₃₈ N ₈ P ₂ RuS ₂	C ₄₀ H ₃₆ N ₂ O ₄ P ₂ RuS ₂
Formula weight	763.90	753.83	809.87	835.84
Temperature / K	293(2)	293(2)	296(2)	296(2)
Wavelength / Å	0.71073	0.71073	0.71073	0.71073
Crystal system	monoclinic	triclinic	monoclinic	triclinic
Space group	P2 ₁ /n	P $\bar{1}$	C2/c	P $\bar{1}$
Unit cell dimensions / Å	$a = 15.0555(2)$ $b = 11.7774(2)$ $c = 20.6408(3)$	$a = 10.1920(7)$ $b = 11.3782(10)$ $c = 16.6300(13)$	$a = 20.053(2)$ $b = 32.567(4)$ $c = 15.2562(15)$	$a = 9.9027(13)$ $b = 15.142(2)$ $c = 15.427(2)$
α / degree	90	98.703(4)	90	86.416(3)
β / degree	108.4750(10)	104.127(5)	120.872(6)	78.599(3)
γ / degree	90	103.997(4)	90	75.717(3)
Volume / Å ³	3471.29(9)	1768.7(2)	8551.8(18)	2197.1(5)
Z	4	2	8	2
Density (calculated) / (mg m ⁻³)	1.462	1.415	1.258	1.263
Absorption coefficient / mm ⁻¹	0.811	0.683	0.572	0.562
F(000)	1568	776	3328	856
Crystal size / mm ³	0.322 × 0.222 × 0.164	0.218 × 0.160 × 0.024	0.090 × 0.060 × 0.030	0.350 × 0.110 × 0.030
Theta range for data collection / degree	2.71 to 26.00 -17 ≤ h ≤ 18	2.644 to 25.671 -11 ≤ h ≤ 12	1.251 to 24.997 -23 ≤ h ≤ 23	1.347 to 26.434 -12 ≤ h ≤ 12
Index ranges	-14 ≤ k ≤ 14 -25 ≤ l ≤ 25	-13 ≤ k ≤ 13 -20 ≤ l ≤ 19	-38 ≤ k ≤ 38 -18 ≤ l ≤ 15	-18 ≤ k ≤ 18 -19 ≤ l ≤ 19
Reflections collected	47703	14516	51358	47497
Independent reflections	6819 [R(int) = 0.1258]	6198 [R(int) = 0.0449]	7527 [R(int) = 0.1548]	8981 [R(int) = 0.0784]
Completeness to theta = 25.242° / %	99.8	94.3	99.9	100.0
Absorption correction	Gaussian	Gaussian	Multi-scan	Multi-scan
Max. and min. transmission	0.8817 and 0.7836	0.9832 and 0.8919	0.7452 and 0.5266	0.7454 and 0.6556
Refinement method	Full-matrix least-squares on F ²			

Table S1. Crystal and refinement data for (**1**), (**2**), (**3**) and (**4**) (cont.)

Compound	1	2	3	4
Data / restraints / parameters	6819 / 0 / 388	6198 / 0 / 408	7527 / 0 / 436	8981 / 0 / 462
Goodness-of-fit on F^2	1.032	1.102	0.999	1.038
Final R indices [$I > 2\sigma(I)$]	R1 = 0.0448, wR2 = 0.1153	R1 = 0.0605, wR2 = 0.1458	R1 = 0.0589, wR2 = 0.1403	R1 = 0.0459, wR2 = 0.0935
R indices (all data)	R1 = 0.0586, wR2 = 0.1273	R1 = 0.0824, wR2 = 0.1611	R1 = 0.1155, wR2 = 0.1771	R1 = 0.0874, wR2 = 0.1086
Largest diff. peak and hole / ($e \text{ \AA}^{-3}$)	1.010 and -1.021	0.956 and -0.812	0.895 and -0.803	0.551 and -0.835

F(000): structure factor in the zeroth-order case; R(int): internal R-value; F^2 : squared structure factor.**Table S2.** Data of the electronic spectra of the complexes (CH_2Cl_2 solutions)

Complex	λ / nm	$\log \epsilon$	Transition
1	234	4.89	IL ($\pi \rightarrow \pi^*$)
	304	4.04	MLCT
	236	4.88	IL ($\pi \rightarrow \pi^*$)
2	276	4.36	IL ($\pi \rightarrow \pi^*$)
	338	3.66	MLCT
	236	4.91	IL ($\pi \rightarrow \pi^*$)
3	266	4.47	IL ($\pi \rightarrow \pi^*$)
	334	4.05	MLCT
	232	4.64	IL ($\pi \rightarrow \pi^*$)
4	298	4.32	IL ($\pi \rightarrow \pi^*$)
	356	3.90	MLCT
	422	3.90	MLCT

IL: intra ligand charge transfer; MLCT: metal ligand charge transfer.

Table S3. Assignments of the vibrational frequencies of the complexes

	Vibrational frequency / cm ⁻¹			
	[Ru(mtz) ₂ (dppb)]	[Ru(mmi) ₂ (dppb)]	[Ru(dmp) ₂ (dppb)]	[Ru(mpca) ₂ (dppb)]
vNH ₂			3437/3394	
vC—H	3137/3051	3114/3051	3127/3058	3152/3046
vCH ₂	2912/2853	2909/2851	2917/2852	2919/2849
v _{as} COOH				1683
vC=O				
vC=N	1588	1590	1619	1580
vC=C+ C=N	1531	1527	1547	1538
v _s COOH				1364
vC—S	1294	1282	1312	1264
vC—S	1183	1143	1159	1153
vP—C _{anel}	1088	1092	1091	1094
vP—C _{alif}	740	741	742	738
vP—C	512	515	516	510
vRu—S	440	438	460	442
vRu—N	423	421	430	420

mtz: 2-mercaptopthiazoline; mmi: 2-mercpto-1-methyl-imidazole; dmp: 4,6-diamino-2-mercaptopurimidine; mpca: 6-mercaptopuridine-3-carboxylic acid; dppb: 1,4-bis(diphenylphosphino)butane.



This is an open-access article distributed under the terms of the Creative Commons Attribution Licence.